Swiss pharma giant Roche Holdings (RHHBY) entered into a research collaboration and licensing agreement with a biotechnology company, Ascidian Therapeutics, for the discovery and development of RNA exon editing therapeutics targeting neurological diseases. Ascidian’s exon editing technology is designed to provide the durability of gene therapy by rewriting RNA, while sharply reducing the risks associated with direct DNA editing and gene replacement. This approach has the potential to treat patients with one ...